Production (Stage)
Akero Therapeutics, Inc.
AKRO
$46.36
-$2.61-5.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -269.44M | -252.06M | -237.22M | -204.18M | -179.27M |
| Total Depreciation and Amortization | 17.00K | 18.00K | 5.00K | 9.00K | 19.00K |
| Total Amortization of Deferred Charges | 673.00K | 607.00K | 553.00K | 505.00K | 797.00K |
| Total Other Non-Cash Items | 19.80M | 18.33M | 16.71M | 15.32M | 13.47M |
| Change in Net Operating Assets | -13.68M | 3.00M | 8.32M | -2.59M | 9.11M |
| Cash from Operations | -262.63M | -230.11M | -211.64M | -190.94M | -155.88M |
| Capital Expenditure | -999.00K | -999.00K | -999.00K | -999.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -648.74M | -108.71M | -111.20M | -309.96M | -183.36M |
| Cash from Investing | -649.74M | -109.71M | -112.19M | -310.96M | -183.36M |
| Total Debt Issued | 0.00 | 10.00M | 10.00M | 10.00M | 10.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 475.59M | 436.69M | 361.20M | 358.88M | 695.85M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.15M | -844.00K | -846.00K | -782.00K | -747.00K |
| Cash from Financing | 474.44M | 445.85M | 370.36M | 368.10M | 705.10M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -437.93M | 106.03M | 46.52M | -133.80M | 365.86M |